KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Net Margin (2016 - 2025)

NovoCure (NVCR) has disclosed Net Margin for 12 consecutive years, with 14.05% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 2683.0% to 14.05% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 20.79% through Dec 2025, up 708.0% year-over-year, with the annual reading at 20.79% for FY2025, 708.0% up from the prior year.
  • Net Margin hit 14.05% in Q4 2025 for NovoCure, up from 22.29% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 3.06% in Q1 2021 to a low of 45.55% in Q2 2023.
  • Historically, Net Margin has averaged 23.55% across 5 years, with a median of 22.17% in 2025.
  • Biggest five-year swings in Net Margin: crashed -4005bps in 2023 and later surged 2683bps in 2025.
  • Year by year, Net Margin stood at 19.86% in 2021, then plummeted by -46bps to 29.05% in 2022, then decreased by -21bps to 35.19% in 2023, then fell by -16bps to 40.88% in 2024, then skyrocketed by 66bps to 14.05% in 2025.
  • Business Quant data shows Net Margin for NVCR at 14.05% in Q4 2025, 22.29% in Q3 2025, and 25.28% in Q2 2025.